Eli Lilly (LLY) Depreciation & Amortization (CF) (2009 - 2026)

Eli Lilly (LLY) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $509.0 million the latest figure, recorded in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $509.0 million, up 9.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 11.69% YoY), and the FY2025 annual result was $2.0 billion, up 13.02% from the prior year.
• Depreciation & Amortization (CF) was $509.0 million for Q1 2026 at Eli Lilly, down from $585.7 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $585.7 million in Q4 2025 and troughed at $348.9 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $430.7 million, with a median of $414.4 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) fell 16.85% in 2023 and increased 25.25% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $375.0 million in 2022, then advanced by 3.31% to $387.4 million in 2023, then grew by 25.25% to $485.2 million in 2024, then advanced by 20.71% to $585.7 million in 2025, then retreated by 13.1% to $509.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $509.0 million in Q1 2026, $585.7 million in Q4 2025, and $470.0 million in Q3 2025.